Sapanisertib
Sapanisertib (also known as TAK-228 or MLN0128) is an investigational drug that is being studied for its potential use in the treatment of various types of cancer. It is a small molecule inhibitor that targets the mammalian target of rapamycin (mTOR) pathway, which is involved in cell growth, proliferation, and survival.
Mechanism of Action[edit | edit source]
Sapanisertib inhibits both mTORC1 and mTORC2 complexes. The mTOR pathway is a critical regulator of cell metabolism, growth, and survival. By inhibiting this pathway, sapanisertib can reduce cancer cell proliferation and induce apoptosis. This dual inhibition is believed to provide a more comprehensive blockade of the mTOR signaling pathway compared to agents that inhibit only mTORC1.
Clinical Development[edit | edit source]
Sapanisertib is currently undergoing clinical trials to evaluate its efficacy and safety in various types of cancer, including breast cancer, lung cancer, renal cell carcinoma, and endometrial cancer. Early-phase clinical trials have shown promising results, with some patients experiencing tumor shrinkage and disease stabilization.
Pharmacokinetics[edit | edit source]
The pharmacokinetics of sapanisertib involve its absorption, distribution, metabolism, and excretion. It is administered orally and has been shown to have a favorable pharmacokinetic profile, with adequate bioavailability and a half-life that supports once-daily dosing.
Side Effects[edit | edit source]
Common side effects of sapanisertib include nausea, fatigue, diarrhea, and hyperglycemia. More serious adverse effects can include pneumonitis and renal dysfunction. Patients undergoing treatment with sapanisertib are closely monitored for these potential side effects.
Research and Future Directions[edit | edit source]
Ongoing research is focused on identifying biomarkers that can predict response to sapanisertib, as well as exploring combination therapies with other anticancer agents. The goal is to enhance the therapeutic efficacy and overcome resistance mechanisms that may develop during treatment.
See Also[edit | edit source]
References[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
